MRNS News and Press, Marinus Pharmaceuticals Inc. From 12/29/23

2023-12-29 14:42:38 ET Summary Today, we revisit Marinus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for rare genetic epilepsies and seizure disorders. The company's main asset is an approved drug called ganaxol...

2023-12-18 23:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Epilepsia publishes two-year open-label extension Marigold trial data of ZTALMY ® (ganaxolone) oral suspension CV in patients with CDKL5 deficiency disorder (CDD) In preliminary results from a Phase 1 multiple ascending dose (MAD) study, the second generation ganaxolone formula...

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 6th Annua...

2023-11-07 14:00:06 ET Marinus Pharmaceuticals, Inc. (MRNS) Q3 2023 Earnings Conference Call November 07, 2023, 08:30 ET Company Participants Sonya Weigle - SVP, IR Scott Braunstein - CEO, President & Chairman Christina Shafer - Chief Commercial Officer J...

2023-11-07 13:31:50 ET More on Marinus Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus Pharmaceuticals, Inc. (MRNS) Q2 2023 Earnings Call Transcript Marinus Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Marinus P...

2023-11-07 07:07:28 ET More on Marinus Pharmaceuticals Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Marinus Pharmaceuticals Q3 2023 Earnings Preview Marinus stock ...

ZTALMY ® (ganaxolone) Q3 net product revenue of $5.4 million; 2023 net product revenue guidance increased to between $18.5 and $19 million Over 75% of patients required for the interim analysis are now enrolled in the Phase 3 RAISE trial in refractory status epilepticus; if the trial...

ZTALMY is approved by the U.S. Food and Drug Administration and the European Commission for appropriate patients with CDKL5 deficiency disorder The program enables physicians to request ZTALMY for eligible patients in geographies where the product is not commercially available and as supp...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...